Pharma Stocks Tumble 5% as Trump's Tariff Shock Jolts Indian Drug Exporters; Nifty Pharma Slips 2%

The tale of tariff not stopping any time soon; just yesterday, U.S. President Donald Trump slapped a 104% retaliatory tariff against China. This trade war is turning to Indian pharmaceutical exporters as well and pharma stocks took a massive hit on April 9. Trump, speaking at a National Republican Congressional Committee event, warned of a "big move on drug import tariffs", sparking panic across global pharmaceutical markets.

Nifty Pharma Index Cracks On April 9

As the tariff threats gained momentum, the Nifty Pharma index fell sharply, dropping over 2% at the opening bell. As of 2 pm, Nifty Pharma is trading at 20,006 down by 1.82%. All major constituents of the index were trading in the red. Top pharma losers included Sun Pharma, Torrent Pharma, Aurobindo Pharma, Lupin, Zydus Lifesciences, and Gland Pharma, with declines of up to 5%.

The pressure has been building for days. Since Trump's initial comments on targeting pharmaceutical imports, the Nifty Pharma index has slumped nearly 5% and is down 14% over the last six months as investors look forward to the risks of exposure to U.S.-focused pharma stocks.

Trump's Pharma Tariff Warning Spooks Markets

U.S. President Donald Trump has said he wants to put huge taxes up to 104% on medicines imported from countries like China. This is his way of hitting back after China added a 34% tax on U.S. goods. But even though the fight is mainly between the U.S. and China, Indian pharmaceutical companies are also getting affected.

Trump wants more medicines to be made inside the U.S. rather than being imported. This has worried Indian drug makers, because India is the biggest supplier of low-cost generic medicines to the U.S. If these new taxes are applied, Indian companies may earn less or even lose money when selling drugs in the U.S.

Since generic drugs already have very thin profit margins, it's hard for Indian companies to increase prices without losing business. If they can't make enough money, they might stop production altogether which could lead to medicine shortages in the U.S.

Hospital Stocks May Offer Some Relief

Centrum in its latest report, says that "while pharma shares are facing headwinds, the broader healthcare sector has some bright spots. On an aggregate basis, for hospital companies under coverage, analysts expect revenue growth of 17.5% YoY to ₹51 billion, driven by an 11% YoY increase in bed capacity and a modest 2% YoY rise in ARPOB (Average Revenue Per Occupied Bed). However, occupancy is projected to decline by ~160 bps QoQ, due to seasonality and festive-related volume dips."

The report further mentioned, "EBITDA for hospital chains is estimated to rise 15% YoY to ₹12 billion, keeping EBITDA margins flat at 23.5% YoY due to ongoing expansion-related costs. PAT (Profit After Tax) is likely to grow at a slower pace of 4% YoY to ₹7 billion. Sequentially, analysts expect ARPOB to rise 1% QoQ, but EBITDA margins may contract by 130 bps, adding short-term pressure on profitability."

Disclaimer: The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.